Inogen (INGN) Company presentation summary

Strategic transformation and market expansion

• Transitioning from a single-product oxygen company to a diversified respiratory care platform, targeting COPD, bronchiectasis, and sleep apnea markets with an estimated 70 million patients in the U.S.

• Portfolio expansion includes new launches: Voxi 5 stationary oxygen concentrator, Simeox airway clearance device, and Aurora CPAP masks, addressing markets worth $0.3B, $0.5B, and $2.2B respectively.

• Leveraging established brand, distribution, and physician trust to drive conversion from oxygen tanks to portable oxygen concentrators, with 59% market penetration opportunity remaining.

• Digital solutions and connected care platforms are being developed to enhance patient engagement and predictive health.

Financial performance and turnaround

• Achieved positive adjusted EBITDA in FY25 for the first time since 2021, with a 107% improvement from FY23 to FY25.

• Revenue grew from $316M in 2023 to $349M in 2025, with mid-single digit growth over the last two years.

• Operating loss improved by 72% and net loss by 78% from FY23 to FY25.

• Gross margin increased by 10% over the same period, reaching 44.2% in FY25.

• Ended 2025 with $121M in cash and no debt.

Capital allocation and future outlook

• $30M share repurchase program underway, with ongoing investments in commercial execution and portfolio expansion.

• Evaluating disciplined M&A opportunities to accelerate growth and profitability.

• Long-term goals include high-single-digit revenue growth, 10%+ adjusted EBITDA, and at least one new product launch per year accretive to gross margin.

• Focused on scaling new products, expanding internationally, and building digital tools to improve outcomes.